Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by pelabooston Dec 13, 2023 7:30pm
327 Views
Post# 35783429

Idle Evening Thoughts

Idle Evening Thoughts
There is a lot going on here, and as my position is quite small, I sometimes wonder why I bother trying to sort it. I do however, like puzzles, and this is a doozy.

I do not think MC is going to exercise those about to expire options. He just got 350K at $1.91 and if there is a buyout greater than $1.91, the new ones would get taken by the buyer. The experts could tell us, but I think he might not even have to put up cash for the options @ $1.91 in the event of a buyout. I am not suggesting a buyout, but it would be better for MC and his options. I would do the same.

Andrew de G. There is no way of knowing what happened. I M O it would have been foolish to fire him, and there are a myriad of reasons for moving on. de G is a finisher, and I am hoping his job is finished. It is curious that there has not be an announcement, but I am not bothered by that.

I should point out to Q, that Dr. Laeufle was there to help design GOBLET and mBC trials.

In conclusion, there is such a lack of clarity, and apparent actual confusion at ONC, I think I will hold, but instead of adding at the end of the month, buy some dividend paying stocks.

Best of luck!




<< Previous
Bullboard Posts
Next >>